FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Federal Register

More Product-specific Guidances for ANDAs

Federal Register notice: FDA makes available additional draft and revised draft product-specific guidances that provide recommendations on ANDA bioequ...

Federal Register

Info Collection Extension on CDRH Appeals Processes

Federal Register notice: FDA seeks comments on an information collection extension entitled Center for Devices and Radiological Health Appeals Process...

Federal Register

Electromechanical Tear Stimulator in Class 2

Federal Register notice: FDA classifies the electromechanical tear stimulator into medical device Class 2.

Federal Register

Integrated Continuous Glucose Monitor is Class 2

Federal Register notice: FDA classifies the integrated continuous glucose monitoring system into medical device Class 2.

Federal Register

Class 2 for Percutaneous Catheter for Hemodialysis

Federal Register notice: FDA classifies the percutaneous catheter for creation of an arteriovenous fistula for hemodialysis access into medical device...

Human Drugs

BioMarin Hold Extended as FDA Seeks More Data

FDA extends a clinical hold on BioMarin Pharmaceuticals PHEARLESS Phase 1/2 study of BMN 307, an AAV5-human phenylalanine hydroxylase gene therapy bei...

FDA General

Put Priority on Data/Technology and Staff: FDA Alliance

The Alliance for a Stronger FDA says that commissioner Robert Califfs first priorities should focus on renewed attention to data and technology modern...

Medical Devices

CDRH Should Increase AI Transparency in Devices: PEW

Pew Charitable Trusts health care products director Liz Richardson says CDRH should increase transparency by requiring more and better information on ...

Medical Devices

FDA Expands Use of Medtronic Freezor Cryoablation

FDA approves Medtronic expanded indications for its Freezor and Freezor Xtra Cardiac Cryoablation Focal Catheters for treating pediatric atrioventricu...

Biologics

Biosimilar Program Review Finds Higher First-Cycle Approvals

An independent review of FDAs user fee program for biosimilars finds that first-cycle approval rates were higher during the first four years of the cu...